Through our integration with Mayo Clinic, Mayo Clinic Laboratories leads the industry in turning test results into clinical answers. Mayo Clinic Laboratories’ comprehensive test menu has been created to aid in screening, diagnosis, and treatment selection across the full spectrum of hematologic disorders. Through our clinical experience, we have developed and validated practice-based, data-driven algorithms that improve patient care, increase efficiency, and reduce costs.
Highlights
Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
On the brink of losing her battle with acute myeloid leukemia, Shannon Camlek arrived at Mayo Clinic as a last hope. Her chances didn’t look good, but with the help of specialized genetic testing, particularly FISH (fluorescence in situ hybridization) studies, doctors were able to detect the specific gene mutations responsible for her symptoms and disease. The test results also helped Shannon’s care team target her treatment accordingly, and finally put an end to what Shannon likens as starring in her own personal horror movie while in search of hope and healing.
One summer morning, James Kypuros awoke to find his toes stiffened like claws. Then he started having falls, which culminated in losing his ability to walk or even sit up without help. Diagnosed with stiff-person syndrome, James wouldn’t find hope or relief until he was treated for glycine receptor antibody syndrome following specialized testing by Mayo Clinic.
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.
In this month's "Hot Topic," Patricia Greipp, D.O., discusses fluorescence in situ hybridization, or FISH testing, particularly related to pediatric patients with hematologic malignancies.
PACE / State of FLIn this month’s “Virtual Lecture,” David Murray, M.D., Ph.D., discusses how immunoglobin light chains are used to detect overexpressed immunoglobins which can be applied to distinguish patients with plasma cell disorders and more.
In a recent discovery by Mayo Clinic Laboratories, a novel hemoglobinopathy category was identified and termed epsilon gamma thalassemia. The first instance of the disorder was found in 2017 when an obstetric patient underwent a routine screening for blood-related illnesses such as sickle cell disease and thalassemia. Upon completion of additional tests, doctors found an abnormality they had never seen before.
PACE / State of FLIn this month's "Virtual Lecture," Anand Padmanabhan provides a general overview and science in the field related to heparin-induced thrombocytopenia (HIT), vaccine-induced thrombotic thrombocytopenia (VITT), and monoclonal gammopathy of thrombotic significance (MGTS), and focuses on impacts related to diagnosis for anti-platelet factor 4-mediated thrombotic syndromes.
This conference will provide reviews and updates about the laboratory and clinical aspects of bleeding and thrombosing disorders. Informational presentations will be supplemented with panel discussions and case presentations, followed by time for participant questions.
This conference will provide a comprehensive approach to the evaluation of frequently encountered blood count abnormalities, along with an update on the diagnosis and management of common and rare nonmalignant blood disorders. The conference will also illustrate the practical application of testing algorithms derived from the Mayo Clinic practice, showing how unnecessary, redundant, and costly laboratory tests can be eliminated while maintaining the highest quality medical care.